Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02952898 · ClinicalTrials.gov registry record · Phase 3
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Phase 3 study, sponsored by Balmoral Medical company.
- Completed
- Registry status
- Phase 3
- Development phase
- 665
- Enrollment target
NCT02952898 is a Phase 3 study that has completed, run by Balmoral Medical company. The registered enrollment target is 665 participants.
The verdict
NCT02952898, a Phase 3 study, has completed, sponsored by Balmoral Medical company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 665 participants
- Enrollment target
Study Summary
This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than placebo in the treatment of actinic keratosis.
Interventions
- DRUG Vehicle gel
- DRUG GDC 695
- DRUG Diclofenac Sodium Gel, 3%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 665 participants |
| Start Date | 2016-10-27 |
| Est. Completion | 2017-09-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02952898
The ClinicalTrials.gov registry entry for NCT02952898 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 665 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Balmoral Medical company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle gel is the first listed.
NCT02952898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02952898 about?
NCT02952898 is a clinical study titled "Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses". This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than placebo in the treatment of actinic keratosis.
What is the current status of trial NCT02952898?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 665 participants. The study started on 2016-10-27. Estimated completion is 2017-09-06.
What interventions are being tested in trial NCT02952898?
The interventions under investigation include: Vehicle gel (DRUG), GDC 695 (DRUG), Diclofenac Sodium Gel, 3% (DRUG).
Who is sponsoring clinical trial NCT02952898?
This trial is sponsored by Balmoral Medical company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.